DISCLAIMER: This page is intended for members of the general public in France only.

The information provided on this site is intended for general information and education for France-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.

Information about the NuvaxovidTM ▼ COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted full marketing authorisation by the EMA for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older in accordance with official recommendations. Nuvaxovid can be administered as booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Important information

For more information about the NuvaxovidTM ▼ COVID-19 Vaccine (recombinant, adjuvanted), download the Package Leaflet.

Report an Adverse Event (AE)

If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.

Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of France.

Agence nationale de sécurité du médicament et des produits de santé (ANSM) et réseau des Centres Régionaux de Pharmacovigilance
Site internet: www.signalement-sante.gouv.fr

Contact Us

Tel: +33 1 82 88 32 29
09:00 - 17:00
Monday - Friday